Skip to main content
IMS Events Main banner

    Bobby W. Sandage, Jr., PhD

    Managing Director
    Paula and Rodger Riney Foundation
    Creve Coeur, Missouri

    Bobby W. Sandage, Jr., Ph.D. has over 40 years of experience in the pharmaceutical industry in drug development and senior management and over 10 years in venture capital investing and currently holds positions in the St. Louis area as Managing Director of the Paula and Rodger Riney Foundation and Lightchain Capital, a venture fund.

    He is a General Partner in Cultivation Capital Life Sciences Fund II, also a venture fund. He is the acting CEO for one of the current portfolio companies, Euclises Pharmaceuticals. Previously Dr. Sandage was President and Chief Executive Officer of Coronado BioSciences, Inc. (NASDAQ: CNDO), an immunotherapy company where he took the company public in 2011. Prior to that, he was Vice President of Covidien (Mallinckrodt) Pharmaceuticals’ oncology research and development program. For 19 years, Dr. Sandage was the Chief Scientific Officer and Executive Vice President of Research and Development, Quality and Manufacturing at Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV) (successor to Interneuron Pharmaceuticals, Inc.), which was acquired by Endo Pharmaceuticals in 2009. Prior to Indevus, he held senior drug development positions at DuPont Merck Pharmaceutical Company, DuPont/American Critical Care, Merrell Dow and Dow Pharmaceuticals.

    Dr. Sandage has extensive experience guiding numerous life sciences companies as a Member of the Board of Directors of NextRNA (Lead Director), Microbial Machines, AI Proteins, Immunophotonics (chairman), Geneoscopy and Endevica Bio. He was previously Board Director at Mateon (NASDAQ: MATN), Arch Oncology, Gentium S.r.l. (NASDAQ: GENT), Osteologix, Inc. (NASDAQ: OLGX), and Genta (NASDAQ: GNTA).

    Dr. Sandage received his undergraduate degree in Pharmacy from the University of Arkansas and his Ph.D. in Clinical Pharmacy from Purdue.

    Disclosure information not submitted.

    Presentation(s):